دورية أكاديمية
أعرض في EDS

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

التفاصيل البيبلوغرافية
العنوان: Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
المؤلفون: Johnny Mahlangu, Howard Levy, Marina V. Kosinova, Heghine Khachatryan, Bartosz Korczowski, Levani Makhaldiani, Genadi Iosava, Martin Lee, Frank Del Greco
المصدر: Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 6, Pp n/a-n/a (2021)
بيانات النشر: Elsevier, 2021.
سنة النشر: 2021
المجموعة: LCC:Diseases of the blood and blood-forming organs
مصطلحات موضوعية: hemophilia, marzeptacog alfa (activated), prophylaxis, recombinant FVIIa, subcutaneous injection, Diseases of the blood and blood-forming organs, RC633-647.5
الوصف: Abstract Background Marzeptacog alfa (activated) (MarzAA), a novel recombinant activated human factor VII (FVIIa) variant, was developed to provide increased procoagulant activity, subcutaneous (SC) administration, and longer duration of action in people with hemophilia. Objectives To investigate if daily SC administration of MarzAA in subjects with inhibitors can provide effective prophylaxis. Methods This multicenter, open‐label phase 2 trial (NCT03407651) enrolled men with severe congenital hemophilia with an inhibitor. All subjects had a baseline annualized bleeding rate (ABR) of ≥12 events/year. Subjects received a single 18 μg/kg intravenous dose of MarzAA to measure 24‐hour pharmacokinetics (PK) and pharmacodynamics (PD), single 30 μg/kg SC dose to measure 48‐hour PK/PD, then daily SC 30 μg/kg MarzAA for 50 days. If spontaneous bleeding occurred, the dose was sequentially escalated to 60, 90, or 120 μg/kg, with 50 days at the final effective dose without spontaneous bleeding to proceed to a 30‐day follow‐up. The primary end point was reduction in ABR. Secondary end points were safety, tolerability, and antidrug antibody (ADA) formation. Results In the 11 subjects, the mean ABR significantly reduced from 19.8 to 1.6, and the mean proportion of days with bleeding significantly reduced from 12.3% to 0.8%. Of a total of 517 SC doses, six injection site reactions in two subjects were reported. No ADAs were detected. One fatal unrelated serious adverse event occurred: intracerebral hemorrhage due to untreated hypertension. Conclusions The data demonstrated that MarzAA was highly efficacious for prophylactic treatment in patients with inhibitors by significantly decreasing bleed frequency and duration of bleeding episodes.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2475-0379
Relation: https://doaj.org/toc/2475-0379
DOI: 10.1002/rth2.12576
URL الوصول: https://doaj.org/article/a9322a7798624e72884c4f60d04eb1af
رقم الأكسشن: edsdoj.9322a7798624e72884c4f60d04eb1af
قاعدة البيانات: Directory of Open Access Journals
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا